Achillion Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
138.59 M |
Public Float |
134.33 M |
Achillion Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.49 |
Market Cap |
$375.95 M |
Shares Outstanding |
138.73 M |
Public Float |
134.93 M |
Address |
VEVA Building 14 Blue Bell Pennsylvania 19422 United States |
Employees | - |
Website | http://www.achillion.com |
Updated | 07/08/2019 |
Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. The company was founded on August 17, 1998 and is headquartered in New Haven, CT. |